CA3301645A1 - Formulations de dihydrokaempférol - Google Patents

Formulations de dihydrokaempférol

Info

Publication number
CA3301645A1
CA3301645A1 CA3301645A CA3301645A CA3301645A1 CA 3301645 A1 CA3301645 A1 CA 3301645A1 CA 3301645 A CA3301645 A CA 3301645A CA 3301645 A CA3301645 A CA 3301645A CA 3301645 A1 CA3301645 A1 CA 3301645A1
Authority
CA
Canada
Prior art keywords
dihydrokaempferol
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3301645A
Other languages
English (en)
Inventor
Taylor OSWALD
Original Assignee
Debut Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debut Biotechnology Inc filed Critical Debut Biotechnology Inc
Publication of CA3301645A1 publication Critical patent/CA3301645A1/fr
Pending legal-status Critical Current

Links

CA3301645A 2023-08-15 2024-08-14 Formulations de dihydrokaempférol Pending CA3301645A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63/532,772 2023-08-15
US63/672,400 2024-07-17

Publications (1)

Publication Number Publication Date
CA3301645A1 true CA3301645A1 (fr) 2025-02-20

Family

ID=

Similar Documents

Publication Publication Date Title
CA3242174A1 (fr) Formulations a base de lipides pour l'administration d'arn
EP4251153A4 (fr) Formulations lyophilisées de tegavivint
EP4099999A4 (fr) Formulations de docétaxel
CA3301645A1 (fr) Formulations de dihydrokaempférol
IL326508A (en) Dihydrokaempferol formulations
CA3301254A1 (fr) Formulations d'ériodictyol
CA3291219A1 (fr) Formulations de pectolinarigénine
CA3291772A1 (fr) Formulations de naringénine
HK40117787A (en) Stable formulations of shr0302
HK40112689A (en) Formulations of radiprodil
EP4319786A4 (fr) Formulations à base de silice d'oligopeptides thérapeutiques et de peptidomimétiques
EP4157262A4 (fr) Formulations pharmaceutiques de pilocarpine r-(+)-lipoate
HK40102138A (en) Formulations of psilocybin
HK40122546A (en) Combination formulation of cedazuridine
HK40106938A (en) Formulations of l-asparaginase
HK40101567A (en) Oral formulations of tenapanor
HK40129881A (zh) 贝祖拉替尼制剂
CA3296099A1 (fr) Formulation solide de pudafensine à administrer par voie orale
HK40090532A (en) Formulations of anti-il-33 antibodies
AU2024900796A0 (en) Formulations
HK40087872A (en) Formulations of cabazitaxel
IL326447A (en) Eriodictyol formulations
CA3277614A1 (fr) Formulations de bezuclastinib
AU2025904106A0 (en) Improved formulations
AU2023903711A0 (en) Formulations